Health & Research Goals
AOD-9604 (Anti-Obesity Drug 9604 / GH Fragment 177-191)
AOD-9604 (Fármaco Antiobesidad 9604 / Fragmento de GH 177-191)
AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal region of human growth hormone (residues 176–19…
Primary Description
AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal region of human growth hormone (residues 176–191), with a tyrosine substitution at the N-terminus that improves stability and potency. Developed in Australia by Metabolic Pharmaceuticals in collaboration with Monash University, it was designed to isolate growth hormone's fat-burning effects while eliminating its growth-promoting, IGF-1-elevating properties. It completed six human clinical trials involving over 900 participants — making it one of the most human-tested peptides in the research community — though it ultimately failed to reach statistical significance in its Phase IIb efficacy endpoint.
Key Benefits
- Fat loss
- No IGF-1 increase
- Cartilage repair
Lyophilized powder is stable. The N-terminal tyrosine substitution improves enzymatic degradation resistance compared to native HGH fragment 176-191. Disulfide bridge between Cys-7 and Cys-14 creates a cyclic conformation that enhances stability. Reconstituted solution should be refrigerated and used within 28 days.
Demonstrated Effects
- Stimulates lipolysis (fat breakdown) via beta-3 adrenergic receptor modulation
- Inhibits lipogenesis — reduces formation of new fat deposits
- Does not elevate IGF-1 — confirmed across all six human clinical trials
- Does not disrupt blood glucose or insulin levels (unlike full HGH)
- No water retention — a notable advantage over full growth hormone protocols
- Human clinical trial data: 2.8 kg weight reduction vs. 0.8 kg placebo over 23 weeks
- Potential joint and cartilage support (reported anecdotally; some research in cartilage regeneration models)
- Well-tolerated safety profile across 900+ trial participants
Proposed Mechanisms of Action
1. Beta-3 Adrenergic Receptor Modulation and Lipolysis
AOD-9604 activates beta-3 adrenergic receptors on adipocytes, triggering the intracellular cAMP cascade that activates hormone-sensitive lipase (HSL) — the primary enzyme for breaking down stored triglycerides into free fatty acids for energy use.
Direct stimulation of fat breakdown in adipose tissue, particularly effective during fasted or low-insulin states.
2. Lipogenesis Inhibition
Beyond breaking down existing fat, AOD-9604 downregulates the enzymatic machinery responsible for creating new fat deposits (lipogenesis). This dual action — increasing breakdown while decreasing formation — creates a pronounced net negative fat balance.
Prevents formation of new fat deposits during the treatment period, compounding the fat loss effect.
3. GH Receptor Dissociation — No IGF-1 Signaling
AOD-9604 contains only the C-terminal lipolytic domain of HGH and physically lacks the receptor binding sites required to activate the GH receptor homodimer. This means it cannot stimulate IGF-1 production, linear growth, or the anabolic pathways responsible for HGH's growth-promoting effects and side effects.
Safety advantage — all fat-burning benefit without growth hormone's endocrinological risks.
Research Evidence & Clinical Data
Investigated Applications
Fat Loss and Body Recomposition
Anecdotal: HighThe dominant use case. Community members report steady, modest fat loss — particularly stubborn abdominal fat — with consistent sub-Q use over 8–20 week cycles. Results are consistently described as gradual but clean, with no muscle loss and none of the side effects associated with full growth hormone (no water retention, no blood sugar disruption, no joint pain from IGF-1 elevation).
Preclinical basis: Direct lipolytic activity via beta-3 AR activation confirmed in adipocyte models. Phase II human trials demonstrated weight reduction significantly greater than placebo. Lipogenesis inhibition shown in fat cell culture.
GH-Like Benefits Without HGH Side Effects
Anecdotal: HighMany biohackers specifically choose AOD-9604 over full HGH protocols because it provides targeted fat-metabolizing effects without the hyperinsulinemia risk, IGF-1 elevation, acromegaly concerns, or joint fluid accumulation seen with exogenous HGH. It is seen as a 'clean' fragment that does one job well.
Preclinical basis: Phase I safety trials confirmed no IGF-1 elevation at any dose tested. Mechanism confirmed to exclude the classical GH receptor binding motif responsible for growth-promoting effects.
Joint and Cartilage Health
Anecdotal: EmergingA smaller subset of community users report joint comfort improvements during AOD-9604 cycles — beyond what would be expected from fat loss alone. Australian researchers have explored its effects in cartilage regeneration models, and some compounding pharmacies include it in joint-targeted formulations.
Preclinical basis: Metabolic Pharmaceuticals and partner researchers identified potential cartilage-protective effects in preclinical work following the weight loss program. Limited human data specific to this application.
Scientific References
- 1.AOD9604 Wikipedia — Clinical Development SummaryWikipedia (citing Metabolic Pharmaceuticals Phase II data)2024
Summary of six completed clinical trials, Phase IIb failure to achieve statistical significance, and regulatory/safety summary across 900+ subjects.
- 2.PubChem CID 71300630 — AOD-9604 Chemical DataNational Library of Medicine / PubChem2024
Verified molecular formula C78H123N23O23S2, MW 1815.10, amino acid sequence, and structural data.
- 3.
Safety Profile
Common Side Effects
- Injection site reactions: redness, swelling, or mild soreness (most common)
- Transient tingling or warmth at injection site
- Mild fatigue, particularly in the first 1–2 weeks
- Rare: sleep disturbances if injected too late in the day
- Rare: elevated liver enzymes (from 900+ participant trials — uncommon and reversible)
- Well-tolerated at standard doses with an extensive human clinical safety record
- Injection site reactions
- Headache (rare)
Contraindications
- Active malignancy — GH-pathway involvement warrants caution despite no IGF-1 elevation
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide components
- Active competitive sports with anti-doping testing — WADA prohibited
- History of significant hepatic impairment — limited safety data
- Pregnancy
- Active cancer
Pre-Use Screening Checklist
Any GH-related peptide is contraindicated with active cancer or high cancer risk, even absent IGF-1 elevation, as a precaution.
Rare liver enzyme elevations noted in clinical trials. Baseline LFTs allow identification of any hepatic response during use.
WADA-prohibited substance. Do not use if subject to drug testing in sanctioned sports.
Although AOD-9604 does not affect glucose, a baseline metabolic panel is useful to track body composition changes objectively during the cycle.
Legal & Regulatory Status
Not FDA-approved for any therapeutic use. Clinical development terminated in 2007 after Phase IIb failure. Listed as a bulk drug substance that may present safety risks. Research chemical status. Not for human therapeutic use in the US.
Prohibited — classified under S2 (Peptide Hormones, Growth Factors, Related Substances) or S0 depending on interpretation. Banned in and out of competition. Athletes subject to anti-doping rules must not use AOD-9604.
No specific COFEPRIS approval. Available as research peptide from vendors. Not authorized as a pharmaceutical product.
Not EMA-approved. Research chemical status. Not authorized for therapeutic use. Compounding regulations vary by member state.
Developed in Australia; had TGA designated status as investigational during clinical trials. Following discontinuation, classified as a Schedule 4 (prescription-only) substance in some contexts. Compounding pharmacies in Australia have historically included AOD-9604 in weight management formulations — regulatory landscape has evolved with increasing peptide restrictions.
Research Protocols
Dosing Protocols
Standard fat loss protocol
Subcutaneous injectionStubborn fat / advanced protocol
Subcutaneous injectionRoutes of Administration
Subcutaneous injection
Most commonStandard sub-Q injection into abdominal fat fold or flank. Use 29–31 gauge insulin syringe. Rotate injection sites.
Pinch skin, insert at 45-degree angle, inject slowly. Apply gentle pressure after withdrawal. Do not rub injection site.
Reconstitution Guide
Bacteriostatic water (preferred) or sterile water for injection
Add bacteriostatic water slowly down the inside wall of the vial. Do not shake — gently swirl until powder is fully dissolved. Solution should be clear and colorless.
Standard: 3 mg vial + 3 mL bacteriostatic water = 1 mg/mL (1000 mcg/mL). To draw 300 mcg: pull 0.3 mL (30 units on a 100-unit insulin syringe). Alternatively: 3 mg + 1 mL = 3 mg/mL; 300 mcg = 0.1 mL (10 units).
Refrigerate at 2–8°C. Use within 28 days. Do not freeze reconstituted solution. Mark vial with reconstitution date.
Lyophilized powder: -20°C for long-term storage (up to 24 months). 2–8°C refrigerator for up to 3 months.
Morning fasted injection is optimal — natural cortisol peak synergizes with fat mobilization. Pre-exercise injection (45–60 min before cardio) is the most popular community practice for maximizing fat oxidation during the session. Avoid injecting within 2–3 hours of a carbohydrate-rich meal as elevated insulin blunts lipolytic effects.
Pharmacokinetics
| Half-Life | Short plasma half-life following sub-Q injection; exact human half-life not formally published. Phase I IV administration data used for safety characterization. Morning injection timing with 30–60 min pre-meal window is based on expected peak action period before food-induced insulin rise blunts lipolysis. |
| Absorption | Sub-Q injection: good bioavailability presumed based on clinical trial efficacy data. Oral formulations were tested in Phase I/II (doses up to 54 mg single dose, 1 mg/day Phase IIb) with demonstrated systemic activity, though sub-Q is preferred in the biohacker community for dose control. |
| Distribution | Distributes to adipose tissue where it exerts primary lipolytic effects via beta-3 AR. Cyclic disulfide structure contributes to proteolytic resistance and extended activity at target tissue level. |
| Metabolism | Standard peptide catabolism by plasma and tissue peptidases. The N-terminal tyrosine substitution and disulfide bridge enhance resistance to enzymatic degradation compared to native GH fragment 176-191. |
| Molecular Structure | 16-amino acid peptide: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with Cys7–Cys14 disulfide bridge). MW: 1815.10 g/mol. CAS: 221231-10-3. N-terminal Tyr replaces native Phe for improved stability. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Body composition (weight, waist measurement)Expect gradual fat loss. Significant results typically appear at weeks 4–6; more pronounced by weeks 8–10.Check: Every 2 weeks
- Liver function (ALT, AST)Flag any elevation above the upper limit of normal. Rare but reported in trial data.Check: Every 8 weeks
- Injection site healthRotate sites to prevent lipodystrophy. Watch for persistent nodules or signs of infection at injection sites.Check: With each injection
Critical Warning Signs
- Allergic reaction — hives, swelling, difficulty breathingDiscontinue immediately. Seek emergency medical care. Document lot number of product for reporting.Urgency: IMMEDIATE
- Persistent sleep disruption or significant anxiety beyond 2 weeksShift injection time to early morning only. If unresolved after one week, reduce dose or discontinue.Urgency: Within 1 week if persistent
- Jaundice, right upper quadrant pain, or significant fatigue suggesting hepatic involvementDiscontinue immediately. Obtain liver function tests. Consult a physician.Urgency: Within 24-48 hours
Featured in Stacking Protocols
Community-researched combinations involving this compound
CJC-1295 + Ipamorelin
Full GH Optimization StackStimulate endogenous GH pulse while AOD-9604 handles targeted fat metabolism
CJC-1295 (GHRH analog) amplifies GH pulse amplitude; Ipamorelin (GHRP) triggers GH pulse timing. Both elevate endogenous GH for anabolic, recovery, and sleep benefits. AOD-9604 contributes direct lipolytic activity without adding IGF-1 burden. Together they address the GH axis comprehensively.
CJC-1295 100 mcg + Ipamorelin 100 mcg sub-Q before bed; AOD-9604 300 mcg sub-Q in the morning fasted.
5-Amino-1MQ
5-Amino-1MQ Synergy StackDual-pathway fat loss — lipolysis activation + NNMT-mediated metabolic optimization
AOD-9604 directly activates beta-3 AR-mediated lipolysis. 5-Amino-1MQ elevates cellular NAD+, activates SIRT1, and shifts adipocyte gene expression toward fat oxidation. Different mechanisms addressing fat loss at the hormonal-signaling and cellular-metabolic levels simultaneously.
AOD-9604 300 mcg sub-Q morning fasted + 5-Amino-1MQ 100 mg oral daily.
Semaglutide
Weight Management Protocol StackComprehensive weight management — appetite suppression + fat metabolism optimization
Semaglutide reduces caloric intake via GLP-1 receptor-mediated appetite suppression and slowed gastric emptying. AOD-9604 independently enhances fat oxidation. Complementary mechanisms that together address both energy intake and energy expenditure from fat stores.
Semaglutide per established protocol; AOD-9604 300 mcg sub-Q on training days or daily. Ensure adequate protein intake as both compounds support fat loss without muscle protection independently.
MOTS-c
Mitochondrial Fitness StackMitochondrial metabolic enhancement + direct lipolysis
MOTS-c is a mitochondrial-derived peptide that improves insulin sensitivity and metabolic flexibility at the cellular level. AOD-9604 provides direct lipolytic signaling. Together they optimize both fat utilization and mitochondrial efficiency.
AOD-9604 300 mcg + MOTS-c 5 mg, both sub-Q in the morning. Weekly or daily MOTS-c dosing per protocol.